BIOMAT Database Logo BIOMAT Database Logo

The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. 2007

C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Division of Infectious Diseases, The Ottawa Health Research Institute, The Ottawa Hospital, Ottawa, Ontario, Canada. claporte@ohri.ca

This genotype panel study investigated the effect of ABCB1 polymorphism in exon 26 (C3435T), exon 21 (G2677T/A), and exon 12 (C1236T) on saquinavir pharmacokinetics and on the expression and activity of P-glycoprotein (P-gp) in peripheral blood monocytic cells (PBMCs). One hundred and fifty healthy volunteers were genotyped to identify 15 TT3435 and 15 CC3435 individuals. In these individuals, saquinavir pharmacokinetics were assessed after administration of a single oral dose of saquinavir 1,000 mg and saquinavir/ritonavir 1,000/100 mg. PBMC P-gp expression and activity were assessed in 15 and 19 subjects. The co-administration of ritonavir on study day 2 caused a significant increase in saquinavir exposure, in both TT3435 and CC3435 individuals. No correlation was observed between the ABCB1 C3435T, G2677T/A, and C1236T polymorphisms, separately and in haplotypes, with saquinavir pharmacokinetics, administered with or without ritonavir and with PBMC P-gp expression and activity. In conclusion, ABCB1 polymorphism has no pronounced effect on saquinavir exposure.

UI MeSH Term Description Entries
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005091 Exons The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA. Mini-Exon,Exon,Mini Exon,Mini-Exons
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006239 Haplotypes The genetic constitution of individuals with respect to one member of a pair of allelic genes, or sets of genes that are closely linked and tend to be inherited together such as those of the MAJOR HISTOCOMPATIBILITY COMPLEX. Haplotype
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.
March 1997, AIDS (London, England),
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients.
February 1998, AIDS (London, England),
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Ritonavir, saquinavir combination--& warning.
September 1995, AIDS treatment news,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.
April 2006, Antimicrobial agents and chemotherapy,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration.
September 2001, British journal of clinical pharmacology,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients.
December 1997, AIDS (London, England),
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
June 2001, British journal of clinical pharmacology,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
April 2010, AIDS alert,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir.
February 2000, European journal of medical research,
C J L la Porte, and Y Li, and L Béïque, and B C Foster, and B Chauhan, and G E Garber, and D W Cameron, and R P G van Heeswijk
Effect of ritonavir on saquinavir metabolism.
June 2000, JAMA,
Copied contents to your clipboard!